Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

202371 citationsJournal Articlehybrid Open Access

Authors

Ana Oaknin · Vall d'Hebron Hospital Universitari

Bhavana Pothuri · Gynecologic Oncology Group

Lucy Gilbert · McGill University Health Centre

Renaud Sabatier · Institut Paoli-Calmettes

Jubilee Brown · Carolinas Healthcare System

Sharad Ghamande · Augusta University Health

Cara Mathews

Abstract

Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Genetic factors in colorectal cancer Ovarian cancer diagnosis and treatment

Publication Details

Published in: Clinical Cancer Research

Volume 29, Issue 22, pp. 4564-4574

DOI: 10.1158/1078-0432.ccr-22-3915

Field-Weighted Citation Impact: 20.98

Command Palette

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Authors

Abstract

Topics & Keywords

Publication Details